OST-HER2 Yields Significant Survival in Pulmonary Metastatic Osteosarcoma
Phase 2b findings demonstrate improved 2-year survival outcomes with OST-HER2 compared with historical control data.
Previous Post
Light Pink Discharge: Causes, Pregnancy Clues & When to See a Doctor
Next Post
In internal FDA town hall, employees raise concerns about staffing, impromptu expert meetings
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago